Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 2:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Remyelination Clear all
Completed Phase 1 Interventional Results available

Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study

NCT02760056
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Liothyronine sodium, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 18, 2018 · Synced Jul 21, 2026, 2:18 PM EDT
Withdrawn Phase 2 Interventional

Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)

NCT00986960
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
repository corticotropin injection, Saline
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jul 21, 2026, 2:18 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

SAD and MAD Study of FTX-101 in Healthy Male Subjects

NCT06617546
View directory record Official record
Conditions
Healthy Volunteers
Interventions
FTX-101, Placebo
Drug
Lead sponsor
Find Therapeutics
Industry
Eligibility
18 Years to 59 Years · Male only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial

NCT01085318
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rebif
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Jul 21, 2026, 2:18 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)

NCT03222973
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BIIB033 (opicinumab), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 58 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
51
States / cities
Cullman, Alabama • Gilbert, Arizona • Berkeley, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Jul 21, 2026, 2:18 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound

NCT07304024
View directory record Official record
Conditions
Central Auditory Processing Disorder, Hearing Impaired (Partially), Hearing, Hearing Abnormality, Hearing Disability, Hearing Disorder, Hearing Disorders, Hearing Impairment, Sensorineural, Hearing Handicap, Hearing Impaired, Hearing Impairment, Hearing Loss, Central Auditory Disease, Noise Exposure, Noise Induced Hearing Loss, Noise-Induced Hearing Loss, Sound Perception, Myelin Degeneration, Myelinopathy, Myelin Integrity, Remyelination, Hidden Hearing Loss, Cocktail Party Skill, Cocktail Party Syndrome, CAPD, Age Problem
Interventions
Clemastine Fumarate Combined With Engineered Sound, Clemastine Fumarate Combined With Pink Noise, Placebo Drug With Engineered Sound, Placebo - Placebo
Combination Product · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
45 Years to 65 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jul 21, 2026, 2:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study

NCT00937677
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Tysabri
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 6, 2011 · Synced Jul 21, 2026, 2:18 PM EDT
Recruiting Not applicable Interventional

The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study

NCT06796504
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Procedure/Surgery: Implant Procedure, Disease-Modifying Therapies (DMTs), Device: Active stimulation, Device: Non-active stimulation
Procedure · Drug · Device
Lead sponsor
SetPoint Medical Corporation
Industry
Eligibility
22 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Atlanta, Georgia • Baltimore, Maryland • Plymouth, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Phase 1 Interventional

Safety Study of BIIB033 in Subjects With Multiple Sclerosis

NCT01244139
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Interventions
BIIB033, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Centennial, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Jul 21, 2026, 2:18 PM EDT
Terminated Phase 2 Interventional

Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis

NCT03536559
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis, Optic Neuropathy, Optic; Neuritis, With Demyelination
Interventions
CNM-Au8, Placebo
Drug
Lead sponsor
Clene Nanomedicine
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2023 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Phase 2 Interventional

Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis

NCT04002934
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Bazedoxifene Acetate
Drug
Lead sponsor
Riley Bove, MD
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Jul 21, 2026, 2:18 PM EDT
Enrolling by invitation Not applicable Interventional

Study to Investigate Vagus Nerve Stimulation Paired With Motor Task for Remyelination and Functional Recovery

NCT06641271
View directory record Official record
Conditions
Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis
Interventions
Closed Loop Trans-Auricular Vagus Nerve Stimulation System, Placebo
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Vaginal Estriol in Multiple Sclerosis

NCT03774407
View directory record Official record
Conditions
Multiple Sclerosis, Neurogenic Bladder
Interventions
vaginal estriol
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Phase 1Phase 2 Interventional

Aerobic Exercise for Remyelination in Multiple Sclerosis

NCT04539002
View directory record Official record
Conditions
Multiple Sclerosis, Sclerosis, Demyelinating Diseases, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Demyelinating Autoimmune Diseases, CNS, Exercise
Interventions
Aerobic exercise, Education Group Control
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Dose Study of a New Formulation of BIIB061

NCT02521545
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BIIB061
Drug
Lead sponsor
Biogen
Industry
Eligibility
20 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 6, 2015 · Synced Jul 21, 2026, 2:18 PM EDT